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Background: Both Leishmania braziliensis and Leishmania amazonensis induce cutaneous disease when injected in
the skin of BALB/c mice. However, L. amazonensis may also visceralize in that strain of mice, infecting mainly the
liver and spleen. In addition, whereas BALB/c mice die with a progressive cutaneous disease when infected by
L. amazonensis, the infection by L. braziliensis is spontaneously cured. In a previous work, we have found that
intravenous injections of L. amazonensis amastigote extract (LaE) potentiated a L. braziliensis infection in BALB/c
mice, and that this infection-promoting activity could be inhibited by the addition of protease inhibitors to the extract.
Methods: In order to detect markers of disease evolution, in the present work we analyzed the specificity of the anti-L.
amazonensis antibody response of L. braziliensis-infected BALB/c mice injected intravenously with saline or LaE,
supplemented or not with protease inhibitors, by the Western blot technique.
Results: IgG1 antibodies recognizing an antigen with apparent molecular weight of 116 kDa were specifically detected
in BALB/c mice that had been turned susceptible to L. braziliensis infection by injections of LaE.
Conclusion: A Th2 immune response (IgG1 antibody-producing) against this 116 kDa antigen, therefore, could be
associated with susceptibility to severe Leishmania infection.
Keywords: Leishmania, Antibody response, Disease progressionBackground
Leishmania parasites proliferate either as extracellular
promastigotes, in the sand-fly vector, or as intracellular
amastigotes, inside the phagolysosome of mammalian
macrophages. Depending on the Leishmania species or
isolate, and on the nature of the host immune response,
the infection can cause distinct forms of disease, ranging
from self-limiting cutaneous lesions to lethal visceral ill-
ness [1–3]. The leishmaniases are difficult to treat, and
parasite resistance against the currently available drugs
is increasing [4].
Although Leishmania braziliensis causes a serious
health problem in South America [5], leading in some
cases to mutilating nasal and/or oral lesions (reviewed in
[6]), few experimental studies on the characterization of* Correspondence: lain@bahia.fiocruz.br
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unless otherwise stated.its antigens, and on the immune response against them,
have been performed [7–9]. Contrasting to what can be
observed in L. braziliensis-infected individuals, some
L. amazonenis-infected individuals develop a progressive
form of leishmaniasis, with multiple, heavily parasitized
cutaneous nodules (diffuse cutaneous leishmaniasis),
which is clearly associated with a failure of the patients’
immune system to mount a parasite-specific Th1 im-
mune response [10, 11].
In the mouse, it has been shown that antibodies of the
IgG1 isotype are produced mainly during a Th2 immune
response, and IgG2a antibodies are produced mainly during
Th1 immune responses [12]. In murine leishmaniasis
models, the Th2 immune response has been associated with
disease susceptibility, whereas the Th1 immune response
has been associated to disease resistance [13]. Similarly to
human beings, different species of Leishmania cause
distinct diseases in mice. The genetic background of the
mouse also affects the outcome of the infection [14–17].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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blot technique, demonstrated that antibodies from in-
fected, healthy individuals and from leishmaniasis pa-
tients reacted with different parasites antigens [18].
Along the same line, a Leishmania infantum recombin-
ant antigen, the k39, has been shown to discriminate
antibodies from infected, asymptomatic individuals from
those of patients with overt visceral leishmaniasis [19, 20].
Antibodies, therefore, may serve as markers of active dis-
ease in leishmaniasis. Prospective studies would need to
be carried out in order to ascertain whether some anti-
bodies produced by asymptomatic, Leishmania-infected
individuals could be markers of resistance or susceptibility
to the development of disease.
Our research group has shown that BALB/c mice,
which are usually resistant to L. braziliensis [21], become
susceptible if they are intravenously injected with a sol-
uble extract of amastigotes of Leishmania amazonensis
(and not of L. braziliensis), and that the supplementation
of the extract with serine-protease inhibitors reduces
this effect [22].
In order to identify possible antigenic markers of
susceptibility to disease associated with the biologic-
ally active L. amazonensis extract, in the present
work the specificity of the anti-Leishmania antibody
response was assessed by Western blot in L. brazi-
liensis-infected BALB/c mice intravenously injected
with the L. amazonensis extract. The extract was
supplemented or not with protease inhibitors and
was injected one week before the infection and every
two weeks thereafter. Antibodies against an antigen
with an apparent molecular weight of 116 kDa were
only detected in the sera of the mice injected with
the biologically active extract (and not in the sera of




Specific pathogen-free, 8-12 week-old, male BALB/c
mice were maintained at the animal facilities of the
Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo
Cruz, Salvador, Bahia, and provided with rodent diet and
water ad libitum. All procedures performed on the ani-
mals were approved (protocol number 004/2004) and
conducted in accordance with norms of the Ethical
Committee in Laboratory Animal Utilization of the
Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo
Cruz, Salvador, Brazil.
Parasites and amastigote extract
The MHOM/Br87/Ba125 L. amazonensis and MHOM/
Br/3456 L.braziliensis strains were used. Their infec-
tivities were maintained by regular inoculations ofpromastigotes in susceptible BALB/c mice and golden
hamsters, respectively. Promastigotes, derived from tissue
amastigotes, were cultured at 23 °C in Schneider’s
medium (Sigma Chemical Co., Saint Louis, MO, USA),
pH 7.2, supplemented with 50 μg/mL of gentamycin and
10 % of heat-inactivated fetal bovine serum (FBS; HIFCS,
Gibco Laboratories, Grand Island, NY, USA) for L. ama-
zonensis, or 20 % FBS for L. braziliensis. L. amazonensis
axenic amastigotes were obtained by the differentiation
of stationary-phase promastigotes in axenic cultures.
They were left to differentiate in Falcon flasks con-
taining 2 × 107 promastigotes/mL in Schneider’s medium
supplemented with 5 % fetal bovine serum, pH 5.4, at
32 °C and 5 % CO2. After 5 days, more than 98 % of cells
were morphologically undistinguishable from amasti-
gotes, as described elsewhere [23]. The amastigotes were
washed three times in ice-cold sterile saline, resus-
pended in ice-cold saline and lysed by exposition to
ultrasound (10 times for 1 min on ice). The lysates
were centrifuged at 16,000 g for 10 min at 4 °C, the su-
pernatants filtered on membranes with 0.22 μm-diameter
pores (Millipore, São Paulo, Brazil) and immediately
stored at -70 °C in small aliquots. These filtered saline
supernatants are called in this report L. amazonensis
extract (LaE). They were shown to be free of bacterial
endotoxin by the Limulus amebocyte enzyme assay
(Biowittaker, MD, USA), and their protein content was
determined by Lowry’s method [24]. Part of the prepared
LaE was supplemented with protease inhibitors (10 mM
phenylmethanesulfonyl fluoride, 5.7 mM N-p-tosyl-L-
phenylalanine chloromethy l kNap-tosyl-L-lysyl chlor-
omethyl ketone etone, 5.4 mM N-p-tosyl-L-lysine
chloromethyl ketone hydrochloride, and 5.9 mM 4-
nitrophenyl hepta-O-acetyl-1-thio-beta-lactoside; Sigma
Chemical Co., St Louis, MO, USA).
Injection of mice with Leishmania extract
Animals from groups of 4 to 5 BALB/c mice received
four 0.2-mL i.v. injections of either LaE or LaE with pro-
tease inhibitors. The injections were separated by an
interval of two weeks, starting one week before the mice
were infected as described below. Each injection con-
tained 200 μg of protein. Control groups of mice re-
ceived four 0.2-mL injections of either saline or saline
plus protease inhibitors.
Murine model of cutaneous leishmaniasis
Ten million L. braziliensis promastigotes, obtained from
stationary-phase culture, were subcutaneously inoculated
into one of the hind footpads of BALB/c mice, seven
days after the first injection of the LaE. The hind pad
thicknesses were weekly measured with a digital caliper
and the lesion sizes estimated by subtracting the thick-
ness of the uninfected pad from the thickness of the
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scribed below.
Evaluation of parasite load
Parasite loads in the footpads were estimated by limiting
dilution [25] six weeks after infection. Briefly, the
infected footpads were macerated in Schneider’s medium
and centrifuged at 50 g for 10 min, at 4 °C. The superna-
tants were re-centrifuged at 1540 g for 10 min at 4 °C
and the pellets were resuspended in Schneider’s
medium, supplemented with 50 μg.mL−1 of gentamycin,
and 20 % FBS. The suspension was serially diluted in
10-fold dilutions and distributed in triplicates in 96-well
culture plates. The number of viable parasites in each
footpad was estimated from the reciprocal of the highest
dilution at which promastigotes could be detected after a
7-day culture at 23 °C, and was expressed as parasites per
milligram of tissue.
Determination of antibody specificity by Western blot
Sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) of LaE was performed on 12 %
polyacrylamide gels using a Mini Protean II apparatus
(Bio-Rad, California, USA). Wells were loaded with LaE
containing 20 μg/mL of protein, resuspended in SDS-
sample buffer and boiled for 4 min, and the electrophor-
esis carried out as described elsewhere [26]. Proteins
were electrophoretically transferred from the gel to
nitrocellulose membranes. The nitrocellulose mem-
branes were cut into vertical strips and blocked for 12 h
with 0.15 M phosphate-buffered saline, pH 7.2 (PBS)
containing 10 % FBS, at 4 °C. Incubation with mouse
sera (diluted 1:1000 in PBS containing 0.05 % of Tween
20 and 10 % of FBS) was carried out during 1 h at room
temperature with mechanical agitation. After five 1-min
washes in PBS, the membranes were incubated during
1 h with appropriately diluted horseradish peroxidase-
conjugated anti-mouse IgG1 or IgG2a (Sigma Chemical
Co., Saint Louis, MO, USA) in PBS containing 0.05 %
Tween 20 and 5 % FBS, at room temperature. The nitro-
cellulose strips were finally incubated with a mixture of
3’3-diaminobenzidine (Sigma Chemical Co., Saint Louis,
MO, USA) and H2O2 in PBS. Naïve mouse sera were
used as negative controls.
Statistical analysis
When the distribution of the data was found to be
Gaussian by the D’Agostino and Pearson’s method, com-
parisons among the groups were performed by ANOVA
followed by the Newman-Keuls’s method. When the dis-
tribution was found to be non-Gaussian, comparisons
among the groups were performed by the Kruskal-
Wallis method followed by the Dunn’s post test. Re-
sults were considered significant when P ≤ 0.05. TheGraphPad Prism program, version 5, was used to perform
the calculations.
Results
Lesion size and parasite burden in experimentally
infected mice
In a previously published work, we have shown that
injection of LaE together with protease inhibitors abol-
ished the enhancing effect of the LaE on the Leishmania
infection in BALB/c mice [22]. We, therefore, have ana-
lysed in the present work not only the antibodies present
in the sera of saline-injected mice, but also the anti-
bodies present in the sera of a group of mice that had
been injected with LaE plus protease inhibitors.
As in previously published work, the four biweekly
intravenous injections of LaE significantly increased the
size of the lesions caused by L. braziliensis in BALB/c
mice (Fig. 1a), whereas the group of mice that received
LaE in the presence of protease inhibitors did not differ
significantly from the control group (mice that received
saline; Fig. 1a).
The number of parasites in the foot pad lesion of
BALB/c mice, infected with L. braziliensis, that received
four biweekly LaE i.v. injections, was significantly higher
than those in animals injected with saline (Fig. 1b). The
infected footpads of the mice injected with protease
inhibitors-treated LaE had on average 100-fold fewer
parasites than the footpads of the mice injected with un-
treated LaE. The group of mice that received LaE in the
presence of protease inhibitors did not differ signifi-
cantly from the control group in terms of parasite load
(Fig. 1b).
Although differences between the groups of mice
treated with LaE and LaE plus protease inhibitors,
both in terms of lesion size and tissue parasitism,
could be clearly seen (Fig. 1), they were not statistically
significant.
Specificity of the antibody response against L. amazonensis
amastigote antigens
One protein with apparent molecular weight of 28 kDa,
and three proteins with apparent molecular weights
from 45 to 54 kDa were only detected by the IgG1 anti-
bodies from mice injected with LaE, regardless of its
supplementation with protease inhibitors (Fig. 2). Add-
itional antigens were recognized only by the sera of the
mice treated with the unsupplemented extract. These
sera stained from 6 to 12 or more bands (Fig. 2, lanes 12
to 16). On the other hand, the sera of the mice injected
with protease inhibitor-supplemented extract specifically
stained only 4 or 5 bands (Fig. 2, lanes 7 to 11). An anti-
gen with apparent molecular weight of 116 kDa was
recognized by all sera of the mice injected with unsup-
plemented LaE (Fig. 2, lanes 12 to 16), and by none of
Fig. 1 Lesion size and parasitism in mouse footpads six weeks after infection. The mice were treated with saline (Saline), saline supplemented
with protease inhibitors (Saline + PI), or with L. amazonensis extract in the presence (LaE + PI) or absence (LaE) of protease inhibitors, as detailed in
the Materials and Methods. a Lesion sizes, measured with a digital caliper as described in the Material and Methods. b Parasite numbers per
milligram of tissue, as assessed by limiting dilution. Each symbol represent the value obtained from an individual mouse. The horizontal lines
represent the median values of the results. *P≤ 0.05; **P ≤ 0.01 (Kruskal-Wallis’s test followed by Dunn’s post test)
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inhibitor-supplemented extract (Fig. 2, lanes 7 to 11).
The recognition pattern of the serum from a particular
mouse injected with unsupplemented extract (Fig. 2,
lane 15) only differed from the recognition patterns of
the sera from mice treated with the protease inhibitor-
supplemented extract (Fig. 2, lanes 7 to 11) by the recog-
nition of that particular antigen.Fig. 2 Reactivity against L. amazonensis antigens, as assessed by Western b
injected with L. amazonensis extract and infected with L. braziliensis. The se
infected mice were treated with saline (Saline; lanes 2 to 6), L. amazonensis
or unsupplemented L. amazonensis extract (LaE, lanes 12 to 16), as detailed
a naïve mouse is shown in lane 1. The positions of molecular weight markSimilar antigens were recognized by IgG2a antibodies
of the L. braziliensis-infected BALB/c mice, injected or
not with LaE, supplemented or not with protease inhibi-
tors (Fig. 3). Three antigens with apparent molecular
weights ranging from 34 to 38 kDa reacted with IgG2a
antibodies only from the sera of mice treated with LaE,
supplemented or not with protease inhibitors (Fig. 3).
No difference in antigen recognition was observed withlot, of IgG1 antibodies in the sera of BALB/c mice that had been
ra were from blood samples collected five weeks after infection. The
extract supplemented with protease inhibitors (LaE + PI, lanes 7 to 11)
in the Materials and Methods. The result obtained with the serum of
ers are shown on the left of the figure
Fig. 3 Reactivity against L. amazonensis antigens, as assessed by Western blot, of IgG2a antibodies in the sera of BALB/c mice that had been
injected with L. amazonensis extract and infected with L. braziliensis. Sera were from blood samples collected five weeks after infection. The
infected mice were treated with saline (Saline; lanes 2 to 6), L. amazonensis extract supplemented with protease inhibitor (LaE + PI, lanes 7 to 11)
or unsupplemented L. amazonensis extract (LaE, lanes 12 to 16), as detailed in the Materials and Methods. The result obtained with the serum of
a naïve mouse is shown in lane 1. The positions of molecular weight markers are shown on the left of the figure
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mented LaE and animals that received LaE supple-
mented with protease inhibitors (Fig. 3, lanes 7 to 16).
Discussion
The transformation from promastigotes to amastigotes
provides the necessary adaptations for the Leishmania to
survive in the mammalian environment, including mech-
anisms to evade or subvert the host immune response,
such as the escape to a safe, protease-free intracellular
vacuole and the production of immunomodulatory mol-
ecules [27–29]. In this study, the presence of a L. brazi-
liensis infection-enhancing activity in soluble extracts of
L. amazonensis amastigotes, as observed previously in
our laboratory [22, 30], was confirmed: larger numbers
of parasites were found in the foot pad of L. braziliensis-
infected BALB/c mice that received LaE than in those
from animals injected only with saline (Fig. 1). In the
present work, the LaE was injected in a relatively large
amount by the intravenous route. In a previously pub-
lished work [30], similar results were obtained when the
intradermal route was used.
It has been reported that the injection of LaE together
with protease inhibitors reverts its infection-enhancing
effects [22]. In fact, it has been shown that Leishmania
amazonensis serine proteases may be disease-aggravating
components of a crude anti-leishmaniasis vaccine [31].
Thus, in the present work we compared the specificity
of the humoral immune response of the mice injected
only with LaE (susceptible to L. braziliensis infection)with that of the response of mice injected with a mixture
of LaE and protease inhibitors (relatively resistant to the
development of L. braziliensis infection).
As shown herein, the nature of the humoral immune
response against L. amazonensis antigens differed in
L. braziliensis-infected mice rendered susceptible by the
intravenous injection of LaE from those of relatively
resistant mice (injected with LaE supplemented with
protease inhibitors or with saline). Quite interestingly,
these differences were most evident for IgG1 antibodies
(Fig. 2), and not for IgG2a antibodies (Fig. 3), a fact
which is consistent with the LaE acting through the pro-
motion of a Th2-dependent immune response. This con-
firm previous results showing increased production of
IL-4 by lymph node cells of LaE-injected mice and the
absence of infection-enhancing effect of this extract in
IL-4-knockout mice [22].
The observed differences in the production of IgG1
antibodies were both quantitative (antibodies of infected
BALB/c mice injected only with saline, or even with pro-
tease inhibitor-supplemented LaE, reacted with fewer
peptides than antibodies from mice injected with unsup-
plemented LaE), and qualitative: a 116 kDa protein band
of L. amazonensis amastigotes was exclusively recog-
nized by sera of unsupplemented LaE-treated BALB/c
mice. It is possible that the presence of IgG1 antibodies
against one or more of these antigens could be a marker
of an infection-promoting immune response induced by
L. amazonensis. These antigens could in fact lead to the
generation and maintenance of a predominant Th2
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ive Th1 response, allowing the progression of the dis-
ease. It would be interesting to find out if sera from
patients with diffuse cutaneous leishmaniasis differ from
those of patients with localized cutaneous leishmaniasis
caused by L. amazonensis by the presence of antibodies
against these antigens.
A Th2 immune response against the protein with ap-
parent MW of 116 kDa might be one of the many escape
mechanisms that have evolved during the thousands of
years of interaction of the parasite with the mammalian
hosts’ immune system. For instance, other Leishmania
molecules, such as the kinetoplastid membrane protein
11 (KMP-11) [32], the Leishmania-homologue of acti-
vated C kinase (LACK) [33], the lipophosphophoglycan
[34] and the Gp63 [35] have been shown, in different
situations, either in vitro or in vivo, to enhance the
Leishmania infection.
The expression of a serine protease with an apparent
molecular weight of 115 kDa by L. amazonensis has
been described by Silva-Lopez and collaborators [36]. In
an electrophoretic-zymographic study performed by our
research group, a protein with the same apparent mo-
lecular weight and with protease activity was found in a
L. amazonensis extract and not in a L. braziliensis ex-
tract (Oliveira & Navarro, unpublished data). It is pos-
sible that this serine protease is the protein recognized
only by antibodies from mice with severe leishmaniasis,
which had been injected with LaE without serine prote-
ase inhibitors in the present work. L. amazonensis serine
protease activity has been shown to enhance the Leish-
mania infection, but the responsible protein has not
been identified [22, 32].
Another interesting fact observed in the present work
was that the untreated L. braziliensis-infected animals
produced antibodies, mainly of the IgG2a isotype, recog-
nizing cross-reactive L. amazonensis antigens (Fig. 3,
columns 1-5). This is in accordance to the fact that these
animals preferentially produce a Th1-dependent immune
response [22, 32]. These cross-reactive antibodies could
be useful for identifying, in Leishmania DNA libraries,
genes encoding recombinant proteins able to elicit po-
tentially protective Th1 immune responses.
It is possible that antibodies against the 116 kDa pro-
tein are produced during the human infection and could
be used as markers of disease susceptibility. This possi-
bility is amenable to investigation by seroepidemiological
studies.
Conclusions
In summary, we investigated the pattern of antigen
recognition by antibodies from BALB/c mice that were
rendered susceptible to L. braziliensis infection by intra-
venous injections of a L. amazonensis extract. We foundthat a protein with a molecular weight of approximately
116 kDa was specifically recognised by antibodies from
those mice. No protein with this molecular weight pos-
sessing infection-enhancing activity has been described
in the literature so far. The immune response against
this protein, therefore, might be detrimental to the de-
velopment of a protective immune response.
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